Addiction Recovery Medications' 'Stigma' Needs To Be Eliminated, Gottlieb Says
Executive Summary
US FDA commissioner tells House committee that culture changes – and label changes – are among the actions the agency is pursuing to address the opioid crisis.
You may also be interested in...
Opioid Policy At US FDA: Over-Promising Or Overreacting?
As President Trump signs SUPPORT Act, former FDA chief counsels offer dueling interpretations of agency's impact in combating opioid crisis.
Opioid Use Disorder: Is Reduced Usage A Better Endpoint Than Abstinence?
Some at patient-focused drug development meeting argue that cutting opioid use should not be considered treatment failure and that medications allowing controlled opioid use may be beneficial.